182 related articles for article (PubMed ID: 9757149)
1. Effect of fluvoxamine therapy on the activities of CYP1A2, CYP2D6, and CYP3A as determined by phenotyping.
Kashuba AD; Nafziger AN; Kearns GL; Leeder JS; Gotschall R; Rocci ML; Kulawy RW; Beck DJ; Bertino JS
Clin Pharmacol Ther; 1998 Sep; 64(3):257-68. PubMed ID: 9757149
[TBL] [Abstract][Full Text] [Related]
2. Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the "Cooperstown cocktail".
Streetman DS; Bleakley JF; Kim JS; Nafziger AN; Leeder JS; Gaedigk A; Gotschall R; Kearns GL; Bertino JS
Clin Pharmacol Ther; 2000 Oct; 68(4):375-83. PubMed ID: 11061577
[TBL] [Abstract][Full Text] [Related]
3. Determinants of interindividual variability and extent of CYP2D6 and CYP1A2 inhibition by paroxetine and fluvoxamine in vivo.
Ozdemir V; Naranjo CA; Shulman RW; Herrmann N; Sellers EM; Reed K; Kalow W
J Clin Psychopharmacol; 1998 Jun; 18(3):198-207. PubMed ID: 9617978
[TBL] [Abstract][Full Text] [Related]
4. Limitations of dextromethorphan N-demethylation as a measure of CYP3A activity.
Kashuba AD; Nafziger AN; Kearns GL; Leeder JS; Gotschall R; Gaedigk A; Bertino JS
Pharmacogenetics; 1999 Aug; 9(4):453-62. PubMed ID: 10780265
[TBL] [Abstract][Full Text] [Related]
5. Combined phenotypic assessment of cytochrome p450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase-2, and xanthine oxidase activities with the "Cooperstown 5+1 cocktail".
Chainuvati S; Nafziger AN; Leeder JS; Gaedigk A; Kearns GL; Sellers E; Zhang Y; Kashuba AD; Rowland E; Bertino JS
Clin Pharmacol Ther; 2003 Nov; 74(5):437-47. PubMed ID: 14586384
[TBL] [Abstract][Full Text] [Related]
6. Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine.
Jeppesen U; Gram LF; Vistisen K; Loft S; Poulsen HE; Brøsen K
Eur J Clin Pharmacol; 1996; 51(1):73-8. PubMed ID: 8880055
[TBL] [Abstract][Full Text] [Related]
7. Quantitation of three-month intraindividual variability and influence of sex and menstrual cycle phase on CYP1A2, N-acetyltransferase-2, and xanthine oxidase activity determined with caffeine phenotyping.
Kashuba AD; Bertino JS; Kearns GL; Leeder JS; James AW; Gotschall R; Nafziger AN
Clin Pharmacol Ther; 1998 May; 63(5):540-51. PubMed ID: 9630827
[TBL] [Abstract][Full Text] [Related]
8. Comparative in vitro and in vivo inhibition of cytochrome P450 CYP1A2, CYP2D6, and CYP3A by H2-receptor antagonists.
Martínez C; Albet C; Agúndez JA; Herrero E; Carrillo JA; Márquez M; Benítez J; Ortiz JA
Clin Pharmacol Ther; 1999 Apr; 65(4):369-76. PubMed ID: 10223772
[TBL] [Abstract][Full Text] [Related]
9. Use of midazolam urinary metabolic ratios for cytochrome P450 3A (CYP3A) phenotyping.
Streetman DS; Kashuba AD; Bertino JS; Kulawy R; Rocci ML; Nafziger AN
Pharmacogenetics; 2001 Jun; 11(4):349-55. PubMed ID: 11434513
[TBL] [Abstract][Full Text] [Related]
10. Variability in drug metabolizing enzyme activity in HIV-infected patients.
Jones AE; Brown KC; Werner RE; Gotzkowsky K; Gaedigk A; Blake M; Hein DW; van der Horst C; Kashuba AD
Eur J Clin Pharmacol; 2010 May; 66(5):475-85. PubMed ID: 20084375
[TBL] [Abstract][Full Text] [Related]
11. Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2.
Ball SE; Ahern D; Scatina J; Kao J
Br J Clin Pharmacol; 1997 Jun; 43(6):619-26. PubMed ID: 9205822
[TBL] [Abstract][Full Text] [Related]
12. Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19).
Christensen M; Tybring G; Mihara K; Yasui-Furokori N; Carrillo JA; Ramos SI; Andersson K; Dahl ML; Bertilsson L
Clin Pharmacol Ther; 2002 Mar; 71(3):141-52. PubMed ID: 11907488
[TBL] [Abstract][Full Text] [Related]
13. Quantification of 3-month intraindividual variability and the influence of sex and menstrual cycle phase on CYP3A activity as measured by phenotyping with intravenous midazolam.
Kashuba AD; Bertino JS; Rocci ML; Kulawy RW; Beck DJ; Nafziger AN
Clin Pharmacol Ther; 1998 Sep; 64(3):269-77. PubMed ID: 9757150
[TBL] [Abstract][Full Text] [Related]
14. The effect of Shoseiryuto, a traditional Japanese medicine, on cytochrome P450s, N-acetyltransferase 2 and xanthine oxidase, in extensive or intermediate metabolizers of CYP2D6.
Nakao M; Muramoto Y; Hisadome M; Yamano N; Shoji M; Fukushima Y; Saruwatari J; Nakagawa K
Eur J Clin Pharmacol; 2007 Apr; 63(4):345-53. PubMed ID: 17297618
[TBL] [Abstract][Full Text] [Related]
15. Effect of St John's wort on the activities of CYP1A2, CYP3A4, CYP2D6, N-acetyltransferase 2, and xanthine oxidase in healthy males and females.
Wenk M; Todesco L; Krähenbühl S
Br J Clin Pharmacol; 2004 Apr; 57(4):495-9. PubMed ID: 15025748
[TBL] [Abstract][Full Text] [Related]
16. A herbal-drug interaction study of keishi-bukuryo-gan, a traditional herbal preparation used for menopausal symptoms, in healthy female volunteers.
Saruwatari J; Takaishi C; Yoshida K; Takashima A; Fujimura Y; Umemoto Y; Abe T; Kitamado M; Shimomasuda M; Muramoto Y; Nakagawa K
J Pharm Pharmacol; 2012 May; 64(5):670-6. PubMed ID: 22471362
[TBL] [Abstract][Full Text] [Related]
17. Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers.
Yeh RF; Gaver VE; Patterson KB; Rezk NL; Baxter-Meheux F; Blake MJ; Eron JJ; Klein CE; Rublein JC; Kashuba AD
J Acquir Immune Defic Syndr; 2006 May; 42(1):52-60. PubMed ID: 16639344
[TBL] [Abstract][Full Text] [Related]
18. Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A Activity) during pregnancy.
Tracy TS; Venkataramanan R; Glover DD; Caritis SN;
Am J Obstet Gynecol; 2005 Feb; 192(2):633-9. PubMed ID: 15696014
[TBL] [Abstract][Full Text] [Related]
19. Six-month, prospective, longitudinal, open-label caffeine and dextromethorphan phenotyping study in children with growth hormone deficiency receiving recombinant human growth hormone replacement.
Kennedy MJ; Davis DA; Smith N; Gaedigk A; Pearce RE; Kearns GL
Clin Ther; 2008 Sep; 30(9):1687-99. PubMed ID: 18840375
[TBL] [Abstract][Full Text] [Related]
20. Drinking Ethanol Has Few Acute Effects on CYP2C9, CYP2C19, NAT2, and P-Glycoprotein Activities but Somewhat Inhibits CYP1A2, CYP2D6, and Intestinal CYP3A: So What?
Gazzaz M; Kinzig M; Schaeffeler E; Jübner M; Hsin CH; Li X; Taubert M; Trueck C; Iltgen-Breburda J; Kraus D; Queckenberg C; Stoffel M; Schwab M; Sörgel F; Fuhr U
Clin Pharmacol Ther; 2018 Dec; 104(6):1249-1259. PubMed ID: 29633238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
